کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10909076 | 1087824 | 2012 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling](/preview/png/10909076.png)
چکیده انگلیسی
Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role. These results confirm a role for p53R2 in both CLO and DEC mechanism of action, demonstrate synergism between these two drugs in this AML model and support the use of this combination in a future clinical trial.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 36, Issue 11, November 2012, Pages 1410-1416
Journal: Leukemia Research - Volume 36, Issue 11, November 2012, Pages 1410-1416
نویسندگان
Karen E. Thudium, Sampa Ghoshal, Gerald J. Fetterly, Jason P. Den Haese, Adam R. Karpf, Meir Wetzler,